# 131I-TLX-101 for Treatment of Newly Diagnosed Glioblastoma (IPAX-2)

> **NCT05450744** · PHASE1 · RECRUITING · sponsor: **Telix Pharmaceuticals (Innovations) Pty Limited** · enrollment: 12 (estimated)

## Conditions studied

- Neoplastic Disease
- Glioblastoma
- Glioblastoma Multiforme

## Interventions

- **DRUG:** 131I-IPA

## Key facts

- **NCT ID:** NCT05450744
- **Lead sponsor:** Telix Pharmaceuticals (Innovations) Pty Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-01
- **Primary completion:** 2026-06
- **Final completion:** 2026-06
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05450744

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05450744, "131I-TLX-101 for Treatment of Newly Diagnosed Glioblastoma (IPAX-2)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05450744. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*